Chimerix (NASDAQ:CMRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Chimerix (NASDAQ:CMRX) in a report released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

CMRX has been the topic of several other research reports. Wedbush reissued a “neutral” rating and issued a $8.55 price target (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. HC Wainwright reissued a “neutral” rating and issued a $8.55 price target (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

Shares of CMRX stock opened at $8.54 on Friday. The firm has a market cap of $801.09 million, a price-to-earnings ratio of -9.09 and a beta of -0.17. Chimerix has a 52 week low of $0.75 and a 52 week high of $8.55. The firm’s 50-day simple moving average is $8.52 and its two-hundred day simple moving average is $5.09.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million. Analysts forecast that Chimerix will post -0.99 earnings per share for the current year.

Institutional Trading of Chimerix

Hedge funds and other institutional investors have recently modified their holdings of the business. Beryl Capital Management LLC purchased a new position in Chimerix during the first quarter valued at approximately $33,421,000. Magnetar Financial LLC purchased a new position in Chimerix during the first quarter valued at approximately $33,337,000. Deerfield Management Company L.P. Series C purchased a new position in Chimerix during the fourth quarter valued at approximately $13,124,000. Alliancebernstein L.P. purchased a new position in Chimerix during the first quarter valued at approximately $31,496,000. Finally, Rosalind Advisors Inc. purchased a new position in Chimerix during the fourth quarter valued at approximately $10,614,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.